Atezolizumab (Tecentriq) plus chemotherapy after surgery did not improve survival in high-risk triple-negative breast cancer, according to a global phase 3 trial.

Bristol Myers Squibb's Opdivo has been approved in a subcutaneous injection formulation by the FDA, making treatment easier for patients and potentially adding years to the product's patent life.

Merck & Co/MSD has won approval in the US for PD-1 inhibitor Keytruda as a ... an FDA breakthrough designation for its PD-L1 inhibitor Tecentriq (atezolizumab) in combination with VEGF inhibitor ...

The addition of sintilimab to neoadjuvant chemoradiotherapy achieved a 60% pathological complete response rate vs 47.3% with ...

The Swiss company was evaluating tiragolumab with its blockbuster PD-L1 inhibitor Tecentriq (atezolizumab ... positive Phase II data for its PD-1 inhibitor Jemperli (dostarlimab) and the ...

Tinengotinib is a novel multi-kinase inhibitor. It may play a role of synergistic effect when combined with ICI. The efficacy and safety data of tinengotinib in combination with atezolizumab in ...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from an expansion cohort of the phase 1b/2 STELLAR-001 trial evaluating zanzalintinib alone or in ...